Cost-effectiveness of hypofractionated radiation therapy versus conventional radiation therapy for unresectable stage III non-small cell lung cancer.

ABSTRACT: Moderately hypofractionated radiation therapy (Hypo-RT) has emerged as a promising alternative to conventional radiation therapy (Con-RT) for patients with unresectable stage III non-small cell lung cancer (NSCLC) receiving concurrent chemotherapy. Emerging evidence suggests that Hypo-RT may offer advantages in overall survival and local control compared to Con-RT. However, despite its clinical benefits, the economic value of Hypo-RT for this specific indication remains underexplored. This study aimed to compare the cost-effectiveness of Hypo-RT with Con-RT in this patient population.Prior prospective and retrospective studies have demonstrated that Hypo-RT achieves superior local disease control without significantly increasing major toxicity in medically inoperable stage III NSCLC. Never

SUBMITTER: Zhang H 

PROVIDER: S-EPMC12750006 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature